summit trial tirzepatide In pts wiht HFpEF and obesity, (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in https://t.co/8ZHm4gySiL According to Packer and colleagues, – Retatrutide Phase 3 TRIUMPH-4 Results:

While both utilize the same active moleculesemaglutidethe delivery systems and auxiliary ingredients differ

Because coinsurance amounts are pegged to the list price, Medicare beneficiaries required to pay coinsurance could face monthly costs of $325 to $430 before they reach the new cap on annual out-of-pocket drug spending established by the Inflation Reduction Act around $3,300 in 2024, based on brand drugs only, and $2,000 in 2025

At Slinic, we use audit-ready processes to ensure every patient receives a single, safe, and effective prescription

If new trial results are negative, we will pursue other avenues

EU 1169/2011